Kathryn J. Collier's most recent trade in Regulus Therapeutics Inc was a trade of 2,604 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regulus Therapeutics Inc | Kathryn J. Collier | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 2,604 | 0 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Kathryn J. Collier | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.90 per share. | 16 Jun 2025 | 2,604 | 65,240 (0%) | 0% | 9.9 | 25,780 | Common Stock |
| Regulus Therapeutics Inc | Kathryn J. Collier | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 2,325 | 0 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Kathryn J. Collier | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. | 16 Jun 2025 | 2,325 | 62,915 (0%) | 0% | 8.8 | 20,460 | Common Stock |
| Regulus Therapeutics Inc | Kathryn J. Collier | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 1,396 | 2,604 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Kathryn J. Collier | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.90 per share. | 16 Jun 2025 | 1,396 | 67,844 (0%) | 0% | 9.9 | 13,820 | Common Stock |
| Regulus Therapeutics Inc | Kathryn J. Collier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 62,500 | 69,240 (0%) | 0% | 0 | Common Stock | |
| Regulus Therapeutics Inc | Kathryn J. Collier | Director | Purchase of securities on an exchange or from another person at price $ 1.82 per share. | 25 Jul 2024 | 4,000 | 6,740 (0%) | 0% | 1.8 | 7,280 | Common Stock |
| Regulus Therapeutics Inc | Kathryn J. Collier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Kathryn J. Collier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Kathryn J. Collier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Kathryn J. Collier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Kathryn J. Collier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) |